Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ramsey Baghdadi

Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.
Set Alert for Articles By Ramsey Baghdadi

Latest From Ramsey Baghdadi

The Sarepta Precedent: The Good, The Bad, And The Ugly

Podcast discussion of three broader precedents stemming from US FDA's original Exondys 51 approval.

Drug Approval Standards FDA

Grading Gottlieb: A Podcast Report Card

Prevision policy experts discuss where US FDA commissioner has been most effective, room for improvement, and what would make for a second successful year.
Leadership FDA

Generics, Budgeting, And The Stubborn Persistence Of Cost Savings

ANDA sponsors want inflation penalty in Medicaid repealed, but long struggle to eliminate IPAB shows just how hard it may be for generics industry to get that 'fix'.  
Generic Drugs Medicaid

Breakthrough Therapy: 'A Lower Bar Of Evidence'?

MedPAC meeting elicits negative view of designation from one members and no one disagreed. Should US FDA reiterate what the special designation actually means?

Review Pathway Drug Approval Standards

US FDA Approval Climate: What Do The Oral Testosterone Reviews Tell Us?

Second go-round for oral testosterone could have marked new boundary on how far FDA is willing to go in approving new entrants to a market with widespread historic off-label use and CV risks.

Advisory Committees Drug Safety

Refuse-to-File Turns 25: New Guidance Changes In Style, But Not Substance

US FDA’s revised draft guidance spelling out its policy on 'refuse-to-file' decisions differs little in substance compared to predecessor issued in 1993. But difference in style is telling sign of the times.

Drug Approval Standards Drug Review
See All